Introduction: Information on the off-label use of Long-Acting Injectable (LAI) antipsychotics in the real world is lacking. In this study, we aimed to identify the sociodemographic and clinical features of patients treated with on- vs off-label LAIs and predictors of off-label First- or Second-Generation Antipsychotic (FGA vs. SGA) LAI choice in everyday clinical practice. Method: In a naturalistic national cohort of 449 patients who initiated LAI treatment in the STAR Network Depot Study, two groups were identified based on off- or on-label prescriptions. A multivariate logistic regression analysis was used to test several clinically relevant variables and identify those associated with the choice of FGA vs SGA prescription in the off-lab...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...
Background Long-acting injectable (LAI) antipsychotics have been shown to reduce risk of relapse in ...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...
Introduction Information on the off-label use of Long-Acting Injectable (LAI) antipsychotics in the ...
Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the...
Scientific background. Long-acting injectable antipsychotics (LAIs) are considered one of the most i...
Background: Long Acting Injectable (LAI) antipsychotics have been claimed to ensure treatment adher...
BACKGROUND: For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed pre...
Background For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predo...
Evidence supports the use of long-acting injectable (LAI) antipsychotics in the treatment and preven...
Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainl...
BACKGROUND: Schizophrenia affects individuals, families, and systems, with treatment primarily being...
Introduction Bipolar disorder requires long-term treatment but non-adherence is a common problem. A...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...
Background Long-acting injectable (LAI) antipsychotics have been shown to reduce risk of relapse in ...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...
Introduction Information on the off-label use of Long-Acting Injectable (LAI) antipsychotics in the ...
Introduction: Information on the off–label use of Long–Acting Injectable (LAI) antipsychotics in the...
Scientific background. Long-acting injectable antipsychotics (LAIs) are considered one of the most i...
Background: Long Acting Injectable (LAI) antipsychotics have been claimed to ensure treatment adher...
BACKGROUND: For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed pre...
Background For many years, long-acting intramuscular (LAI) antipsychotics have been prescribed predo...
Evidence supports the use of long-acting injectable (LAI) antipsychotics in the treatment and preven...
Long-Acting Injectable Antipsychotics (LAIs) are used to overcome non-compliance in psychoses, mainl...
BACKGROUND: Schizophrenia affects individuals, families, and systems, with treatment primarily being...
Introduction Bipolar disorder requires long-term treatment but non-adherence is a common problem. A...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...
Background Long-acting injectable (LAI) antipsychotics have been shown to reduce risk of relapse in ...
Until relatively recently, long-acting injectable (LAI) formulations were only available for first-g...